Therapeutic Effects and Adverse Drug Reactions are Affected by Icotinib Exposure and CYP2C19 and EGFR Genotypes in Chinese Non-Small Cell Lung Cancer Patients

Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancers in a Multiethnic Malaysian Patient Population

(2014) Chong-Kin Liam et al.   Asian Pacific Journal of Cancer Prevention

Relationships between EGFR Mutation Status of Lung Cancer and Preoperative Factors - Are they Predictive?

(2014) Katsuo Usuda et al.   Asian Pacific Journal of Cancer Prevention

Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

(2013) Wei-Xiang Qi et al.   Asian Pacific Journal of Cancer Prevention

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

(2013) S. Alimujiang et al.   Asian Pacific Journal of Cancer Prevention

Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients

(2013) Jin-Bing Pan et al.   Asian Pacific Journal of Cancer Prevention

Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling

(2013) Zhenzhen Gao et al.   BIOMEDICINE & PHARMACOTHERAPY

Icotinib: kick-starting the Chinese anticancer drug industry

(2013) D Ross Camidge   LANCET ONCOLOGY

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers

(2012) Can-Jun Ruan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

(2011) Fenlai Tan et al.   LUNG CANCER

Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry

(2011) Dongyang Liu et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

(2010) Qiong Zhao et al.   LUNG CANCER

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

(2008) Toshimi Takano et al.   JOURNAL OF CLINICAL ONCOLOGY